Literature DB >> 17397010

HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages.

Rajatava Basu1, Syamal Roy, Peter Walden.   

Abstract

Visceral leishmaniasis is a protozoal disease caused by the intracellular parasites Leishmania donovani and L. chagasi/infantum, and it is usually deadly if not treated. To date, no vaccine exists for prophylaxis or immunotherapy, nor has it been established which effector mechanisms of the immune system are most instrumental against the parasites. Recent reports have suggested that CD8(+) T cells, in addition to CD4(+) T cells, might play major roles in the defense against infection and in the cure of the disease. To identify epitopes recognized by CD8(+) T cells that can be used for immune monitoring to investigate the role of these cells in human visceral leishmaniasis, as well as in vaccine development, we scanned the entire sequence of the leishmanial protein kinetoplastid membrane protein (kmp)-11 with overlapping nonapeptides. Thirty peptides that specifically trigger interferon- gamma secretion by human CD8(+) T cells were identified. Four T cell lines with specificities for different peptides recognize Leishmania-infected autologous macrophages, which proves that kmp-11 is processed and presented via the major histocompatibility complex class I pathway of infected cells. Kmp-11 is thus a candidate antigen for the development of T cell vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17397010     DOI: 10.1086/513439

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells.

Authors:  Subha Banerjee; June Ghosh; Subha Sen; Rajan Guha; Ranjan Dhar; Moumita Ghosh; Sanchita Datta; Bikramjit Raychaudhury; Kshudiram Naskar; Arun Kumar Haldar; C S Lal; K Pandey; V N R Das; Pradeep Das; Syamal Roy
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

2.  DNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasis.

Authors:  Robson A A da Silva; Natália M Tavares; Dirceu Costa; Maiana Pitombo; Larissa Barbosa; Kyioshi Fukutani; Jose C Miranda; Camila I de Oliveira; Jesus G Valenzuela; Aldina Barral; Manuel Soto; Manoel Barral-Netto; Cláudia Brodskyn
Journal:  Acta Trop       Date:  2011-08-22       Impact factor: 3.112

3.  Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells.

Authors:  Antje Hoff; Ana-Cristina Bagû; Thomas André; Günter Roth; Karl-Heinz Wiesmüller; Brigitte Gückel; Roland Brock
Journal:  Cancer Immunol Immunother       Date:  2010-05-29       Impact factor: 6.968

4.  High-throughput high-resolution class I HLA genotyping in East Africa.

Authors:  Rebecca N Koehler; Anne M Walsh; Eric E Sanders-Buell; Leigh Anne Eller; Michael Eller; Jeffrey R Currier; Christian T Bautista; Fred Wabwire-Mangen; Michael Hoelscher; Leonard Maboko; Jerome Kim; Nelson L Michael; Merlin L Robb; Francine E McCutchan; Gustavo H Kijak
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

5.  Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.

Authors:  Dirlei Nico; Carla Claser; Gulnara P Borja-Cabrera; Luiz R Travassos; Marcos Palatnik; Irene da Silva Soares; Mauricio Martins Rodrigues; Clarisa B Palatnik-de-Sousa
Journal:  PLoS Negl Trop Dis       Date:  2010-11-09

6.  Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.

Authors:  Rajatava Basu; Suniti Bhaumik; Arun Kumar Haldar; Kshudiram Naskar; Tripti De; Syamal Kumar Dana; Peter Walden; Syamal Roy
Journal:  Infect Immun       Date:  2007-10-01       Impact factor: 3.441

7.  In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.

Authors:  Negar Seyed; Farnaz Zahedifard; Shima Safaiyan; Elham Gholami; Fatemeh Doustdari; Kayhan Azadmanesh; Maryam Mirzaei; Nasir Saeedi Eslami; Akbar Khadem Sadegh; Ali Eslami Far; Iraj Sharifi; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

8.  Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.

Authors:  Angamuthu Selvapandiyan; Ranadhir Dey; Sreenivas Gannavaram; Ines Lakhal-Naouar; Robert Duncan; Poonam Salotra; Hira L Nakhasi
Journal:  J Trop Med       Date:  2011-09-06

9.  Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan.

Authors:  Brima M Younis; Mohamed Osman; Eltahir A G Khalil; Francesco Santoro; Simone Furini; Rebecca Wiggins; Ada Keding; Monica Carraro; Anas E A Musa; Mujahid A A Abdarahaman; Laura Mandefield; Martin Bland; Toni Aebischer; Rhian Gabe; Alison M Layton; Charles J N Lacey; Paul M Kaye; Ahmed M Musa
Journal:  Mol Ther       Date:  2021-03-27       Impact factor: 11.454

10.  Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection.

Authors:  Sandip Mukherjee; Budhaditya Mukherjee; Rupkatha Mukhopadhyay; Kshudiram Naskar; Shyam Sundar; Jean Claude Dujardin; Anjan Kumar Das; Syamal Roy
Journal:  PLoS Negl Trop Dis       Date:  2012-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.